AAP
KYTX icon

Arax Advisory Partners’s Kyverna Therapeutics KYTX Stock Holding History

Arax Advisory Partners’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$95 Hold
11
– – ﹤0.01% 3619
2025
Q4 		$103 Hold
11
– – ﹤0.01% 3822
2025
Q3 		$66 Buy
+11
New +$44 ﹤0.01% 3525

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Arax Advisory Partners's KYTX Position: Q1 2026 in Review

Arax Advisory Partners held its Kyverna Therapeutics (KYTX) position steady in Q1 2026 at 11 shares worth $95. The position accounts for ﹤0.01% of the portfolio, ranked #3619.

Arax Advisory Partners first reported a position in KYTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $103 in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Arax Advisory Partners held 11 shares of Kyverna Therapeutics worth $95 as of Q1 2026.
  • Arax Advisory Partners left its Kyverna Therapeutics share count unchanged in Q1 2026.
  • Kyverna Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3619 holding.
  • Arax Advisory Partners first reported a position in Kyverna Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Arax Advisory Partners's Kyverna Therapeutics position peaked at $103 in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.